Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8+ T cells

Sci Adv. 2022 Feb 4;8(5):eabl9783. doi: 10.1126/sciadv.abl9783. Epub 2022 Feb 2.

Abstract

eEF-2K has important roles in stress responses and cellular metabolism. We report here a previously unappreciated but critical role of eEF-2K in regulating the fate and cytocidal activity of CD8+ T cells. CD8+ T cells from eEF-2K KO mice were more proliferative but had lower survival than their wild-type counterparts after their activation, followed by occurrence of premature senescence and exhaustion. eEF-2K KO CD8+ T cells were more metabolically active and showed hyperactivation of the Akt-mTOR-S6K pathway. Loss of eEF-2K substantially impaired the activity of CD8+ T cells. Furthermore, the antitumor efficacy and tumor infiltration of the CAR-CD8+ T cells lacking eEF-2K were notably reduced as compared to the control CAR-CD8+ T cells. Thus, eEF-2K is critically required for sustaining the viability and function of cytotoxic CD8+ T cells, and therapeutic augmentation of this kinase may be exploited as a novel approach to reinforcing CAR-T therapy against cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • CD8-Positive T-Lymphocytes*
  • Elongation Factor 2 Kinase / metabolism*
  • Mice
  • Neoplasms* / therapy
  • Peptide Elongation Factors

Substances

  • Peptide Elongation Factors
  • Eef2k protein, mouse
  • Elongation Factor 2 Kinase